Navigation Links
Cord Blood America Revenues Up 37 Percent to $5.67 Million in 2011
Date:4/16/2012

LAS VEGAS, April 16, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that revenues for 2011 increased 37 percent to $5.67 million compared to $4.13 million in 2010.  The Company announced a gross profit increase in 2011 of $1.3 million, or 52 percent, to $3.8 million.

"We are pleased with the increase in revenues," said Matthew Schissler, co-founder and CEO.  "We are also pleased that we continue to reduce overhead and administrative expenses. Our efforts to reduce these expenses have paid and will continue to pay dividends for the Company and its investors."

The entire 10K is available at www.sec.gov

"Revenues were generated from our operations in the U.S., with our major storage facility in Las Vegas, and by our ownership or affiliations with companies in South America and Europe and revenue generation also occurred from placenta collection services for major tissue banks," Mr. Schissler said.

"The Company continues to report increases in revenue and gross profits.  While progress has been made on the expense side, we will continue to evaluate future actions that reduce both future costs and existing obligations.  We need to be very aggressive in this strategy," said Matthew Schissler, co-founder and CEO.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

 


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
2. Measuring blood flow to monitor sickle cell disease
3. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
5. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
6. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
7. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Study finds chronic abnormal brain blood flow in Gulf War veterans
11. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... London UK (PRWEB) , ... September 21, 2017 ... ... , a QuintilesIMS company, who enable the world’s most progressive pharma and biotech ... 2,000 clinical trials at top pharma and biotech events in Q4. , DrugDev ...
(Date:9/21/2017)... ... September 21, 2017 , ... When a downtown ... response was swift and efficient thanks to the continuing efforts of members of ... of more than 50 stakeholders, including officials from area counties and cities, Renewable ...
(Date:9/21/2017)... ... September 21, 2017 , ... Biorez, ... election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., to serve as ... a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction that is designed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Cybrexa Therapeutics , ... to the role of chief scientific officer. In this role, Dr. Paralkar will ... president and CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):